» Articles » PMID: 23032072

Striatal Adenosine Signaling Regulates EAAT2 and Astrocytic AQP4 Expression and Alcohol Drinking in Mice

Overview
Date 2012 Oct 4
PMID 23032072
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Adenosine signaling is implicated in several neuropsychiatric disorders, including alcoholism. Among its diverse functions in the brain, adenosine regulates glutamate release and has an essential role in ethanol sensitivity and preference. However, the molecular mechanisms underlying adenosine-mediated glutamate signaling in neuroglial interaction remain elusive. We have previously shown that mice lacking the ethanol-sensitive adenosine transporter, type 1 equilibrative nucleoside transporter (ENT1), drink more ethanol compared with wild-type mice and have elevated striatal glutamate levels. In addition, ENT1 inhibition or knockdown reduces glutamate transporter expression in cultured astrocytes. Here, we examined how adenosine signaling in astrocytes contributes to ethanol drinking. Inhibition or deletion of ENT1 reduced the expression of type 2 excitatory amino-acid transporter (EAAT2) and the astrocyte-specific water channel, aquaporin 4 (AQP4). EAAT2 and AQP4 colocalization was also reduced in the striatum of ENT1 null mice. Ceftriaxone, an antibiotic compound known to increase EAAT2 expression and function, elevated not only EAAT2 but also AQP4 expression in the striatum. Furthermore, ceftriaxone reduced ethanol drinking, suggesting that ENT1-mediated downregulation of EAAT2 and AQP4 expression contributes to excessive ethanol consumption in our mouse model. Overall, our findings indicate that adenosine signaling regulates EAAT2 and astrocytic AQP4 expressions, which control ethanol drinking in mice.

Citing Articles

Evidence that Alzheimer's Disease Is a Disease of Competitive Synaptic Plasticity Gone Awry.

Huang Z J Alzheimers Dis. 2024; 99(2):447-470.

PMID: 38669548 PMC: 11119021. DOI: 10.3233/JAD-240042.


Neuroimmune modulators as novel pharmacotherapies for substance use disorders.

Grodin E Brain Behav Immun Health. 2024; 36:100744.

PMID: 38435721 PMC: 10906159. DOI: 10.1016/j.bbih.2024.100744.


Ceftriaxone as a Novel Therapeutic Agent for Hyperglutamatergic States: Bridging the Gap Between Preclinical Results and Clinical Translation.

Abulseoud O, Alasmari F, Hussein A, Sari Y Front Neurosci. 2022; 16:841036.

PMID: 35864981 PMC: 9294323. DOI: 10.3389/fnins.2022.841036.


Blood-brain barrier permeability in response to caffeine challenge.

Lin Z, Jiang D, Liu P, Ge Y, Moghekar A, Lu H Magn Reson Med. 2022; 88(5):2259-2266.

PMID: 35754146 PMC: 9420773. DOI: 10.1002/mrm.29355.


Mechanisms Underlying Aquaporin-4 Subcellular Mislocalization in Epilepsy.

Szu J, Binder D Front Cell Neurosci. 2022; 16:900588.

PMID: 35734218 PMC: 9207308. DOI: 10.3389/fncel.2022.900588.


References
1.
Kim K, Lee S, Kegelman T, Su Z, Das S, Dash R . Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol. 2011; 226(10):2484-93. PMC: 3130100. DOI: 10.1002/jcp.22609. View

2.
Parkinson F, Ferguson J, Zamzow C, Xiong W . Gene expression for enzymes and transporters involved in regulating adenosine and inosine levels in rat forebrain neurons, astrocytes and C6 glioma cells. J Neurosci Res. 2006; 84(4):801-8. DOI: 10.1002/jnr.20988. View

3.
Hinson S, Roemer S, Lucchinetti C, Fryer J, Kryzer T, Chamberlain J . Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008; 205(11):2473-81. PMC: 2571922. DOI: 10.1084/jem.20081241. View

4.
Young J, Yao S, Sun L, Cass C, Baldwin S . Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica. 2008; 38(7-8):995-1021. DOI: 10.1080/00498250801927427. View

5.
Abulseoud O, Miller J, Wu J, Choi D, Holschneider D . Ceftriaxone upregulates the glutamate transporter in medial prefrontal cortex and blocks reinstatement of methamphetamine seeking in a condition place preference paradigm. Brain Res. 2012; 1456:14-21. PMC: 3922613. DOI: 10.1016/j.brainres.2012.03.045. View